# A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

> **NCT04626674** · PHASE1 · RECRUITING · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 83 (estimated)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **GENETIC:** delandistrogene moxeparvovec

## Key facts

- **NCT ID:** NCT04626674
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-23
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-02-29
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626674, "A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04626674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*